25 May 2013
Keywords: cytogen, mabs, acquired, worldwide, rights, unipath, cancer-based
Article | 15 February 1993
Cytogen has acquired worldwide rights to Unipath's cancer-based
monoclonal antibody R&D program. Unipath is the medical products arm of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com